Delcath reports positive results from two independent studies on CHEMOSAT and HEPZATO KIT in liver cancers

DELCATH SYSTEMS, INC.

CHEMOSAT study: 91% disease control rate, 18.2% complete response in liver tumors; median hepatic PFS 52 weeks overall.
CHEMOSAT in uveal melanoma: median hepatic PFS 69 weeks; in cholangiocarcinoma: 38 weeks.
HEPZATO KIT first-line: median OS 22.4 months, hepatic PFS 17.6 months vs 8.8 months for immunotherapy.
HEPZATO KIT second-line: median PFS 22.2 months; hepatic PFS not reached vs 14.7 months for immunotherapy.
Both studies published in peer-reviewed journals (ESMO GI and Annals of Surgical Oncology).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.